Pharmacologic Substance
AstraZeneca Abandons Roxadustat’s US Future while Retaining Collaboration with FibroGen in China
FibroGen, roxadustat, China, Ultrasonography, AstraZeneca, Collaboration, chemotherapy-induced anemia, Retained
Interchangeable Humira Biosimilar Simlandi Joins Market Battle with Unique High-Concentration Formula
Simlandi, interchangeable, Biosimilars, Market
Venatorx Confident in Quick Resolution of Manufacturing Concerns for Cefepime-Taniborbactum Antibiotic Despite FDA Setback
United States Food and Drug Administration, Venatorx, CID, 2024-02-23, cefepime-taniborbactam, Manufacture
FDA Approves Allecra’s Exblifep, Giving Headstart Over Competition in Complicated Urinary Tract Infections
Urinary tract infection, Complicated
Novavax Secures $400 Million Settlement with Gavi to Resolve COVID-19 Vaccine Contract Dispute
Gavi, Novavax, Settlement and Resettlement
ViiV’s Long-Acting Cabenuva Outperforms Daily Oral Therapy in Phase III Study
cabenuva, Daily, Standard of Care, Adherence (attribute), HIV, Participant, daily
AbbVie CEO Gonzalez to Step Down, Robert Michael named Successor in Seamless Transition
Gonzalez, AbbVie’s, company’s, Transition Mutation
FDA Approves Xolair (Omalizumab) for Reducing Severe Outcomes from Multiple Food Allergies
Xolair, United States Food and Drug Administration, omalizumab, Hypersensitivity, Food, Reduced, Severe (severity modifier)
Daiichi Sankyo Invests $1 Billion to Expand German Facility for Precision Cancer Antibody-Drug Conjugates
Daiichi, Sankyo, Antibody-Drug Conjugates